Atlas Trials

Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma

Clinical trial NCT01468311 · TERMINATED

Trial details

NCT number
NCT01468311
Sponsor
National Cancer Institute (NCI)
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hodgkin DiseaseHodgkin Lymphoma
Start date
2011-10-11
Primary completion
2014-11-16
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.